Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025

Accessibility StatementSkip Navigation Highlights of the REZOLVE-AD Phase 2b Study: Week 16 Efficacy | 24 µg/kg q2w | 18 µg/kg q2w | 24 µg/kg q4w | Placebo | | | | --- | --- | --- | --- | --- | --- | | (high dose) | (middle dose) | (low dose) | | | | | Primary Endpoint | N=104 | N=106 | N=110 | N=73 | | | Mean improvement inEASI score frombaseline | 61% | 58% | 53% | 31Â | % | | | p<0.001 | p<0.001 | p<0.001 | | | | Key SecondaryEndpoints | N=73 | N=104 | N=106 | N=110 | | | | 42% | 46% | 34% | | | | EASI-7 ...